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Breast cancer is still a deadly disease despite major
achievements in targeted therapies designed to
block ligands or ligand-binding subunits of major
tyrosine kinase receptors. Relapse is significant
and metastases deleterious, which demands novel
strategies for fighting this disease. Here, we report
a proof-of-concept experiment demonstrating that
small peptides interfering with the transmembrane
domain of the tyrosine kinase epidermal growth
factor receptor ErbB2 exhibit anticancer properties
when used at micromolar dosages in a genetically
engineered mouse model of breast cancer. Different
assays demonstrate the specificity of the ErbB2-tar-
geting peptide, which induces long-term reduction of
ErbB2 phosphorylation and Akt signaling consistent
with reduced tumor cell proliferation and increased
survival. Microcomputed tomography analysis es-
tablished the antimetastatic activity of the peptide
and its impact on primary tumor growth. This reveals
the interior of the cell membrane as an unexplored
dimension for drug design.
INTRODUCTION
Breast tumorigenesis is a multistep process leading cells to un-
dergo genetic and epigenetic transformations eventually giving
rise to invasive carcinoma with bad prognosis (Bombonati and
Sgroi, 2011). The ErbB family of tyrosine kinase receptors plays
a key role in breast carcinogenesis through complex signaling
networks made of multiple heterodimeric combinations of
ErbB receptors (Eccles, 2011). Although having no identified
ligand, ErbB2 is amplified and overexpressed in high-grade
ductal carcinoma (Ross and Fletcher, 1999) and in high-grade in-1714 Cell Reports 8, 1714–1721, September 25, 2014 ª2014 The Auflammatory breast cancer (Charafe-Jauffret et al., 2004) thereby
being largely involved in the induction and development of the
malignant transformation (Freudenberg et al., 2009). Several
studies revealed the importance of the dimeric status of ErbB2
triggering signaling cascades including the MAPK and PI3K/
Akt pathways (Freudenberg et al., 2009). ErbB2 promotes cell
proliferation, supports survival, and also favors invasion and
metastasis. Most of the ErbB2-positive cancers resist to
ErbB2-targeted therapies or tyrosine kinase inhibitors (Arteaga
et al., 2012). The heterodimerization capacity of ErbB2 with
ErbB1 or ErbB3 and activation of compensatory signaling path-
ways are considered as important resistance mechanisms (Ya-
maguchi et al., 2014). An ideal therapeutic strategy would hence
be to interfere with receptor interactions by preventing dimeriza-
tion and oligomerization in order to block redundant or compen-
satory downstream signaling pathways. Mounting evidence
nowadays demonstrate that the transmembrane domains act
as crucial regulators of integral membrane receptors interac-
tions. Strikingly, the transmembrane domains of ErbB family
members are also critically involved in ErbB signaling not only
by stabilizing dimerization but also by controlling structural rear-
rangements favoring optimal conformational positioning for
kinase activation (Cymer and Schneider, 2010). Hence, point
mutations in the transmembrane domain of the murine homolog
of ErbB2 (mErbB2 also called Neu) lead to constitutive activation
of the receptor. This observation led Gullick and collaborators to
show that expression in cells of short transmembrane mErbB2
proteins lacking any other interacting domains reduced cell
growth both in vitro and in vivo (Lofts et al., 1993). Thus, blocking
transmembrane-domain-dependent mErbB2 dimerization may
represent an avenue for the design of a novel type of drugs
with anticancer properties. Indeed, after successful inhibition
of brain tumor growth when disrupting the nontyrosine kinase re-
ceptor Neuropilin-1 oligomerization by administration of a syn-
thetic peptide antagonizing its transmembrane domain (Nasarre
et al., 2010), we decided to explore how a similar strategy would
apply for the inhibition of mErbB2 and how this may efficientlythors
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Figure 1. Demonstration of the Peptide-
Based Inhibition of NeuNT/ErbB2 Receptor
(A) Analogy-based model of the nearly full-length
monomeric and dimeric ErbB2 receptor illustrating
the interaction between native transmembrane
domains (TMDs) or with a peptide mimicking
the TMD.
(B and C) Bacterial Adenylate Cyclase Two-Hybrid
System demonstrating the specificity and capacity
of positive (B) or negative (C) homo- or hetero-
dimerization of NeuNT TMD.
(D) Demonstration of the dose-dependent anti-
proliferative effect of MTP-NeuNT in NT193 cells
derived from MMTV-NeuNT tumor-bearing mice
using a MTT assay.
(E) Demonstration of the prolonged and intensified
antiproliferative effect of the peptide over time.
(F) Proliferation assay (MTT) respectively from left
to right on 4T1, MCF7, SKBR3, MDA-MB-231 cell
lines treated with MTP-NeuNT or vehicle (LDS) at
107 and 106 M for 24 hr. Only cells expressing
ErbB2 exhibit reduced proliferation when treated
with the therapeutic peptide.
Data are presented as mean ± SEM from triplicate
experiments. p values were determined by Mann-
Whitney test in comparison to control LDS at 107
and 106 M for 24 hr. ***p < 0.0001, **p < 0.001
compared to vehicle. n.s., not significant. Scale
bars, 50 mm. See also Table S1.impact the metastatic process that remains nowadays the major
challenge in breast cancer. We conducted this proof-of-concept
experiment in an animal model of genetically induced breast
tumors in which primary tumors are driven by the expression of
a transforming mutant mErbB2 (NeuNT, exhibiting a mutation
in its transmembrane domain leading to the constitutive activa-
tion of the receptor) oncogene under the MMTV mammary spe-
cific promoter (MMTV-NeuNT). Besides allowing the analysis in
fully immune-competent mice, this model also gives rise to
lung metastasis and has been clearly shown to be highly predic-
tive of drug efficacy in human (Roberts et al., 2012). Here, we
report that long-term triweekly intraperitoneal administration of
low doses of a synthetic Membrane Targeting Peptide (MTP)
mimicking the transmembrane domain of NeuNT (MTP-NeuNT)
triggers sustained inhibition of the Akt pathway thereby impeding
tumor cell growth and metastasis. Hence, this proof-of-conceptCell Reports 8, 1714–1721, Sepexperiment demonstrates that drugs
targeting the transmembrane domain
of tyrosine kinase receptors offer a cred-
ible alternative to classical approaches
focused on extra or intracellular domains.
RESULTS AND DISCUSSION
Molecular Modeling of NeuNT
Transmembrane Domain
The substitution of a valine for a glutamic
acid in the transmembrane domain (TMD)
of the mErbB2 receptor leads to the
constitutive activation of the receptor ina dimeric state and carcinogenesis (Weiner et al., 1989). We first
performed molecular modeling of TMD dimerizing interface to
better predict the interaction of a TMD-NeuNT mimicking pep-
tide (MTP-NeuNT) with the native TMD. Figure 1A shows the
MTP-NeuNT in the context of the nearly full-length dimeric
NeuNT receptor. This model is based on the recently published
molecular dynamics study of EGFR dimers (Arkhipov et al.,
2013). Our approach illustrates how the transmembrane domain
kindly accommodates to the interface of the active receptor as
previously suggested (Bagossi et al., 2005). Our model supports
the idea of an active role of the TMD to control the proper dimeric
and conformational organization of the receptor as recently
described for EGFR (Endres et al., 2013). The crossing angle of
the transmembrane helices at 45 degrees involves small resi-
dues in the core of the dimer. Such conformation was shown
to be among the most stable in previously published ErbB2tember 25, 2014 ª2014 The Authors 1715
TMDmodels (Bocharov et al., 2010). Thus, in the case of NeuNT
receptor, MTP-NeuNT peptide would inhibit signaling by inter-
fering with homodimerization of the TMD of the NeuNT receptor
through direct competition for binding to the dimerization inter-
face.When lockedwithin the dimerization interface,MTP-NeuNT
peptide would also prevent further heterodimerization by
reducing its availability for any other interactions.
NeuNT Transmembrane Domain Sequence Exhibits
Highly Specific Interactions
To address the specificity of MTP-NeuNT, we performed a two
hybrid-like screening using the BACTH system (Karimova
et al., 2001). Constructions encoding several TMD containing
GxxxG motifs were used to measure interactions with NeuNT
TMD (Figures 1B and 1C). This assay confirmed the high propen-
sity of the MTP-NeuNT peptide to dimerize with NeuNT TMD
when compared with positive control GPA-GPA (Glycophorin
A) interaction or negative GPAm-GPAm interaction (mutated
nondimerizing version of Glycophorin-A TMD in which glycine
83 is replaced by an isoleucine). NeuNT TMD sequence showed
no heterodimerization with various GxxxG-containing se-
quences including Glycophorin A, Neuropilin-1, Vascular endo-
thelial growth factor receptor 1, Vascular endothelial growth
factor receptor 2, Vascular endothelial growth factor receptor
3, or Integrin Beta 1 (Figure 1C). The MTP-NeuNT sequence
showed strong heterodimerization capacity with the mouse
ErbB2 sequence (mErbB2) or the human ErbB2 sequences
(hErbB2). Moreover, the NeuNT sequence significantly inter-
acted with the murine orthologous of ErbB1 (mErbB1), ErbB3
(mErB3), and ErbB4 (mErbB4) but not with the human ortholo-
gous of these receptors (Figures 1B and 1C). Strikingly, using
proximity ligation assay (Duolink system), we were able to
show that MTP-NeuNT significantly reduced the number of
ErbB2/ErbB3 dimer/oligomers in two different cell lines in-
cluding the NeuNT and MCF7 cells (Figure S1). Thus, this part
of the study confirmed stable homo- and heterodimer formation
of the ErbB2 TMD (Bennasroune et al., 2004; Cymer and
Schneider, 2010) and allowed us to define the dimerizing and
antagonizing capability of the MTP-NeuNT peptide while
demonstrating the specificity of interactions.
MTP-NeuNT Exhibits a Long-lasting Inhibitory Effect
There was no cellular model allowing the study of NeuNT
signaling in a native context. To circumvent this issue, we devel-
oped a cell line derived from tumors collected in MMTV-NeuNT
mice (NT193 cell line). This cell line exhibits epithelial and meta-
static properties and constitutively expresses the mutated
version of ErbB2. We performed a dose-response analysis to
characterize the inhibition of cell proliferation that was obtained
with 108 M of the peptide reaching a maximal effect at 106 M
(21% at 106 M versus vehicle, p < 0.001, Mann-Whitney test)
(Figure 1D). Moreover, we found that treating the cells with 106
M had a prolonged and intensified effect as seen by a significant
2- to 3-fold amplification of the inhibitory effect when measuring
cell proliferation at 48 and 72 hr post-treatment (68% at 48 hr
and 41% at 72 hr compared to control, p < 0.001 Mann-Whit-
ney test). This long-lasting effect is dose dependent because
107 M of the MTP-NeuNT peptide only showed mild reduction1716 Cell Reports 8, 1714–1721, September 25, 2014 ª2014 The Auover time (17% at 24 hr, p < 0.0001 at 48 hr, p = 0.24,
and 12% at 72 hr, p < 0.0004, compared to control, Mann-
Whitney test) (Figure 1E). This persistent effect is consistent
with our previous confocal microscopy observations demon-
strating that similar TMD peptides enter the cells within a time
frame of 30–50 min and that they can be imaged at the mem-
brane up to 72 hr postincubation before endocytosis and degra-
dation (Nasarre et al., 2010; Popot et al., 2011). Hence, we
verified that MTP-NeuNT inhibited proliferation of another mu-
rine breast cancer cell line (4T1 cells) and ErbB2 expressing
human breast cancer lines (MCF7, SKBR3) but had no effect
on human MDA-MB-231 cells lacking expression of ErbB2 at
the protein level (Figure 1F). Interestingly, partial knockdown of
ErbB2 in MCF7 cells was correlated to decreased activity of
MTP-NeuNT peptide (Figure 2A). The specificity of the peptide
was also confirmed in gain-of-function experiments in which
ErbB2 was expressed in MDA-MB-231 cells. Indeed, the prolif-
eration of MDA-MB-231 ErbB2-positive cells was significantly
decreased when treated with 106 M of MTP-NeuNT (Figure 2B).
MTP-NeuNT Inhibits ErbB2 Phosphorylation and Akt
Phosphorylation
Because we observed an ErbB2-dependent negative impact
of MTP-NeuNT on tumor cell expansion, we investigated how
this peptide affects ErbB2 signaling. We observed a significant
45% reduction of ErbB2 phosphorylation (normalized to total
ErbB2) in MTP-NeuNT-treated NT193 cells compared to control
conditions (lithium dodecyl sulphate [LDS], p = 0.0078, Mann-
Whitney test, Figure 2C) using a phosphospecific ELISA assay.
Moreover, we also found a 58%decrease of Akt phosphorylation
(p < 0.0001, chi-square test) in NT193 cells treated for 1 hr (Fig-
ure 2D). Strikingly, we found sustained inhibition of Akt phos-
phorylation up to 72 hr consistent with long-term inhibition of
cell proliferation (Figure 2E). Similarly, Erk1/2 phosphorylation
(the second most important signaling pathway triggered by
NeuNT/ErbB2) was significantly reduced in the presence of the
peptide (Figure 2E). Hence, MTP-NeuNT is able to inhibit the
proproliferative and survival signaling cascades triggered by
the NeuNT/ErbB2 receptor. From a therapeutic point of view,
the inhibition of the Akt pathway highlights an interesting antitu-
moral potential of the peptide because the Akt pathway is hyper-
active in more than 70% of breast cancers (Grunt and Mariani,
2013) and is considered as one of the major source of tumor
cell survival and metastasis (Kim and Chung, 2002).
MTP-NeuNT Improves Overall Survival of
MMTV-NeuNT Mice
MMTV-NeuNT transgenic mice develop stochastic mammary
adenocarcinoma approximately from 12 weeks of age (Muller
et al., 1988). To determine how MTP-NeuNT would affect breast
tumor growth, we administrated intraperitoneal bolus of 15 mg/kg
of the peptide (a concentration equivalent to 106 M) three times
a week starting when the first palpable tumor reached a volume
of 200 mm3. Tumor occurrence was identical in both groups
(100%) within a similar time frame to reach 200 mm3 tumors
(214 days in control versus 218 days in MTP-NeuNT group, p =
0.95, Mann-Whitney test) before administration of treatments.
A waterfall plot of best response (determined between day 21thors
A B
C D
E
Figure 2. Characterization of MTP-NeuNT
Inhibitory Effect
(A) We were able to generate two different clones
of MCF7 cells partially knockdown for ErbB2.
These clones showed reduced sensitivity to MTP-
NeuNT almost proportional to the level of knock-
down. Data are presented as mean ± SEM from
triplicate experiments.
(B) To better confirm the link between cell sensi-
tivity and expression level of ErbB2, we performed
gain-of-function experiments in MDA-MB231 cells
(lacking ErbB2 expression) becoming sensitive
to MTP-NeuNT when expressing ErbB2. Data
are presented as mean ± SEM from triplicate
experiments.
(C) Demonstration of the inhibition of ErbB2
phosphorylation (ELISA assay). Data are pre-
sented as mean ± SEM from triplicate experi-
ments.
(D) Akt phosphorylation (western blot) in NT193
cells treated with 106 M of MTP-NeuNT.
(E) Demonstration of the sustained inhibition of
Akt phosphorylation after 2 days treatment also
accompanied by significant reduction of Erk1/2
phosphorylation.and day 28 of treatment according to the RECIST criteria) re-
vealed that 100% of the treated animals responded to the treat-
ment with 33%of SD (stable disease, <30%decrease of target
lesion) and 67% with PR (partial response >30% decrease of
target lesion) (Figure 3A). This high response rate translated
into a marked survival benefit (Figure 3B) with a median survival
increase up to 122% compared with untreated animals
(73.5 days in control animals versus 90 days in MTP-NeuNT-
treated animal, p = 0.0182, log-rank test). We also found that
the delay for the appearance of second tumors (defined as the
second palpated tumor) was doubled in MTP-NeuNT-treated
mice as compared to control mice (4.6 days in control group
versus 10.4 days in MTP-NeuNT-treated animals, p = 0.0066,
Mann-Whitney test) thereby demonstrating an overall impact
on disease progression. In comparison to our results for MTP-
NeuNT that already reduced primary tumor onset and growth,
a genetically delivered TGFb antagonist had no effect on tumorCell Reports 8, 1714–1721, Seplatency in MMTV-NeuNT mice (Yang
et al., 2002). Thus, antagonizing the
TMD of NeuNT appears as a potent ther-
apeutic strategy.
Antimetastatic Activity of MTP-
NeuNT
The occurrence of lung metastasis is
a critical step in breast cancer progres-
sion and linked to disease-associated
death (Chambers et al., 2002). Thus, we
decided to monitor whether the improved
survival of mice treated with MTP-NeuNT
could reflect reduced lung metastatic
colonization. To this end, we analyzed
the serial mCT images collected atdifferent time points of the protocol. Figure 3C is showing repre-
sentative examples of the metastases detected in the control or
the MTP-NeuNT-treated group. A waterfall plot of best response
(determined between week 7 and week 8 of treatment according
to the RECIST criteria) revealed that 100% of the treated animals
responded to the treatment with 20% of SD and 80% with PR
including two individuals above 90% of decrease in metastasis
volume (Figure 3D). Quantitative measurements of the total num-
ber of metastasis in randomly selected five of ten control mice
and five of ten MTP-NeuNT mice revealed a 2.4-fold decrease
(n = 26 detectable metastases in control versus n = 11 metasta-
ses in MTP-NeuNT group) in treated animals after 8 weeks of
treatment (Figure 3E). Determination of metastases volumes
also revealed a 4.5-fold decrease when comparing cumulated
volumes of metastases in mice of MTP-NeuNT group with those
of the control group (cumulated volumeCV = 78.3mm3 in control
versus CV = 17.5 mm3 in MTP-NeuNT group) (Figure 3F). Hence,tember 25, 2014 ª2014 The Authors 1717
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Figure 3. Effect of MTP-NeuNT In Vivo
(A) Demonstration of the inhibitory effect of NeuNT
peptide on primary tumors volumes between day
21 and day 28 of treatment. The Waterfall graph
represents the percent change in tumor volume of
individual treated animals (gray bars, n = 9)
compared to the averaged tumor volume
increased determined in the control group (dark
bar, n = 10). This demonstrates that 100% of the
treated animals responded to the treatment with
30% stable disease and 70% partial response.
(B) Kaplan-Meyer survival curve demonstrating
a significant increased survival of the treated ani-
mals compared to the control animals.
(C) Representative example of lung metastases
seen from mCT 3D surface rendering or single
sagittal and axial sections of the lungs in a control
animal (left panel) and in a treated animal (right
panel). Lung metastases are surrounded in red,
heart in dashed yellow, and orange arrowheads
point to ribs.
(D) Waterfall graph representing the percentage
change in metastases volume of individual treated
animals (gray bars, n = 5) compared to the aver-
aged metastases volume increase determined in
the control group (dark bar, n = 5) between weeks
7 and 8 of treatment.
(E and F) (E) Regression curves indicating that
MTP-NeuNT treatment decreases the number of
lung metastasis over time and (F) the cumulated
volume of lung metastases.mCT analysis revealed a significant antimetastatic effect of MTP-
NeuNT characterized by both a reduction of the number and size
of the lesions.
MTP-NeuNT Inhibits Metastasis Proliferation and
Prevents Parenchymal Invasion
Because micrometastases (<1 mm in diameter) are difficult to
analyze by mCT, we decided to perform histological examination
of the lungs to further analyze the antimetastatic effect of MTP-
NeuNT. This allowed us to confirm an overall 1.8-fold reduction
of the mean number of lung metastasis (Figure 4A). Interestingly,
a detailed analysis allowed us to distinguish between intravas-
cular and parenchymal metastases (Siegel et al., 2003) to reveal
a 2.6-fold decrease of the number of parenchymal metastases in
the MTP-NeuNT-treated group compared to the control group.
This result suggests that the peptide is able to reduce paren-
chymal invasion, presumably because impeding extravasation
of metastasizing cells forming emboli in blood vessels. We also
found a general 2.7-fold decrease of tumor cell proliferation in1718 Cell Reports 8, 1714–1721, September 25, 2014 ª2014 The Authorslung metastases using Ki67 staining (Fig-
ure 4B). Moreover, we observed a 1.9-
fold increase of TUNEL-positive cells in
the metastases of treated animals illus-
trating that the peptide impaired tumor
cell survival (Figure 4C). Hence, Akt phos-
phorylation was 4.9-fold decreased (Fig-
ure 4D). Altogether these data demon-
strate that the therapeutic peptide isable to slow down proliferation and extravasation of metastatic
cells and survival as a consequence of Akt pathway inhibition.
Conclusions
We believe that the transmembrane domain of tyrosine kinase
receptors is an eligible domain for drug design because this
underestimated domain is crucial for the control of receptor acti-
vation (Arkhipov et al., 2013; Endres et al., 2013). Our study dem-
onstrates that a peptide mimicking the TMD of the mutant
mErbB2 (NeuNT) is able to specifically antagonize NeuNT,
mouse and human ErbB2 thereby inhibiting phosphorylation of
the receptor and downstream signaling. This long-lasting inhibi-
tory property translated into improved survival and strong reduc-
tion of metastasis growth of mice presenting genetically induced
mammary tumors. Strikingly, micromolar dosage was sufficient
to trigger significant therapeutic benefit with no histological
sign of toxicity (Figure S2). This unique strategy may apply to
other tyrosine kinase receptors, therefore opening an avenue
for drug design.
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Figure 4. Histological Analysis of Lung
Metastases
(A) Representative microphotographs illustrating
extravasating metastasis and pure intravascular
metastasis in the control and treated group,
respectively. Systematic quantification of the
number of metastasis reveals a 2-fold reduction in
MTP-NeuNT-treated animals.
(B) Demonstration of the antiproliferative activity
of the peptide by systematic counting of Ki67-
positive cells.
(C) Demonstration of the proapoptotic effect of the
peptide using the TUNEL method.
(D) Demonstration of the inhibition of the Akt
pathway by systematic counting of phospho-Akt-
positive cells in metastasis.
In (B)–(D), the left part is showing representative
images of Ki67, TUNEL, or phospho-Akt-positive
cells (immunocytochemistry, scale bars, 50 mm).
The right parts are presenting the corresponding
quantitation, p values are determined by Mann-
Whitney test, *p < 0.05; **p < 0.001; ***p < 0.0001.
Data are presented as mean ± SEM.EXPERIMENTAL PROCEDURES
Cell Culture
All cell media were supplemented with 10% fetal calf serum (Gibco), 100 IU/ml
penicillin, and 100 mg/ml streptomycin (Sigma), and cultures were performed
at 37C, 5% CO2. MDA-MB-231 (ErbB2 negative), MCF7 (ErbB2 positive),
SKBR3 (overexpressing ErbB2) cells were grown in Dulbecco’smodified Eagle
medium (DMEM, Gibco). Murine Balb/c 4T1 (ErbB2 positive) cells were grown
in RPMI1640 (Gibco). NT193 cells were derived from MMTV-NeuNT primary
tumors.
Peptides
Peptides have been synthesized by the Peptide Specialty Laboratories GmbH
by automatic peptide synthesis (Fmoc chemistry). The peptide corresponding
to the TM sequence of NeuNT: TFIIATVEGVLLFLILVVVVGILIKRR (in one-letter
code, amino acid T654 to R680 according to Swissprot entry P06494) is referred
as MTP-NeuNT. Peptides purity estimated by RP-HPLC was more than 90%
according to manufacturer indication.
Modeling of the NeuNT Receptor Dimer and MTP-NeuNT
The nearly full length of the monomeric and the dimeric ErbB2 receptors were
modeled by homology using MODELLER 9.11. The multitemplates strategy
was employed using as templates the recent model of EGFR obtained by mo-
lecular dynamics and the X-rays and NMR structures of the domains available
for the murine ErbB2 receptor. These domains are the extracellular region
(PDB.ID 1N8Y), the kinase domain (PDB.ID 3PP0), and the right-handed dimer
model of the TM domain. The 3D structure of the missing part of the intracel-
lular domain of the murine ErbB2 was modeled using the prediction serverCell Reports 8, 1714–1721, SepI-TASSER. The homology models of the mono-
meric and the dimeric ErbB2 receptors were ener-
getically minimized before their insertion in a lipidic
bilayer.
Estimation of MTP-NeuNT Dimerization:
BACTH Method
A bacterial two-hybrid system based on the
recombination of adenylate cyclase CyaA from
Bordetella pertussis was used to measure both
homo- and heterodimerization propensities of
transmembrane domains of interest. We havemodified the BACTH pKTN25 and pUT18 plasmids so that they encode for
hybrid proteins containing a signal sequence followed by the different TMDs
of interest and the T25 and T18 fragments of adenylate cyclase. Double trans-
formation in BTH101 (cya-) E. coli cells, cell growth and induction, and beta-
Galactosidase assay in 96-well arrays were performed on a TECAN machine.
Peptide sequences used in this study are summarized in Table S1.
Immunocytochemistry
Cells were grown on sterile glass coverslips for 1 day before immunofluores-
cence staining. The cells were fixed with 4% formaldehyde (FA) for 10 min.
The samples were gently rinsed with PBS before adding the blocking solution
(FCS 5%) for a minimum of 30 min. Cells were permeabilized using 1 3 PBS
with 0.1% Tween 20 for 5 min. Primary HER2/ErbB2 (Cell Signaling #2242,
diluted 1/50 from stock solution) antibody diluted in 5% fetal calf serum
(FBS)-PBS was added to the cell over night at room temperature (RT). After
three washes of 5 min secondary antibody (donkey anti-rabbit, Jackson
ImmunoResearch 711-165-152 diluted 1/1,000 from stock) was added at RT
for 90 min. After washing in PBS, the cell nuclei were stained with DAPI
(40,6-diamidino-2-phenylindole, 1/30,000 in water) for 10 min. Glass coverslips
were finally mounted on microscopy glass slides using a polymerization
medium (FluorSave reagent, Calbiochem-Merck cat# 345789).
Histology
Giemsa Staining
Lungs (left lobes) were removed and fixed overnight in 4%FA. Following exten-
sive washes organs were dehydrated in 100% ethanol for a day and then
embedded in paraffin. Samples were stored at RT. The paraffin-embedded tis-
sue blocks sections (7 mm thickness) were dewaxed and rehydrated throughtember 25, 2014 ª2014 The Authors 1719
100%Toluene (2 washes of 15min) then 100%–70%alcohol (10min each) and
then stainedwithGiemsa stain (RAL#320310-0125, diluted 1/50 from stock so-
lution) for 2 hr at 37C. After extensive washing, differentiation is achieved with
0.5% aqueous acetic solution for 30 s. Sections are then rapidly dehydrated in
70%–100% alcohol baths with rapid dips in each bath before final wash in
toluene for 15min. Slides were mounted in Eukitt (Sigma) for long term conser-
vation and microscopic observation.
Hematoxylin-Eosin
The paraffin embedded kidney and liver sections were dewaxed and rehy-
drated as described above. Sections were stainedwith hematoxylin (Surgipath
#01562E) for 5 min and washed with running tap water. Differentiation was
accomplished in acid alcohol solution for 7 s followed by thorough wash
(running tapwater for at least 10min). Sections were incubated in eosin (Harris,
RAL# 31273-7) for 10 s, rinsed again, and dehydrated as described above
before mounting in Eukitt (Sigma #03989).
Cell Proliferation
In vitro cell proliferation was monitored using MTT (3-[4,5 -Dimethylthiazol-2 -
yl]-2,5-di phenyl tetrazolium bromide) proliferation assay according to manu-
facturer’s instruction (Sigma, M2128). Optical density was determined at
570 nm using an ELISA plate reader spectrophotometer (EL800, BioTek Instru-
ments). NT193 cells were seeded at a density of 10,000 cells per well in a 96-
well plate; the cells were then incubated with various peptide concentrations
(ranging from 109 to 106 M) or corresponding vehicle (LDS, ranging from
0.72 to 720 mM). In vivo cell proliferation was determined by quantification of
Ki67-positive cells. Dewaxed sections were boiled with the antigen retrieval
sodium citrate buffer (pH 6) for 20 min (Sigma #CO759). After incubation
with blocking solution (PBS Triton-100X +5%NGS) for 20min, the avidin/biotin
blocking solutions were added on the tissue for 15 min, respectively (Blocking
kit from Vector Laboratories SP-2001). The primary anti-Ki67 antibody
(Thermo Scientific, RM-9106) was added in blocking solution overnight at a
dilution of 1/200, whereas secondary antibody (goat anti-rabbit, Vector Labo-
ratories, #PI-1000) was added at a dilution of 1/200 in PBS for 1 hr at room tem-
perature. Revelation was performed using Elit Vectastain kit (PK-6100). All
specimens were counterstained with hematoxylin.
Determination of Apoptosis
Sections were prepared as above to determine apoptosis using the ApopTag
Plus Peroxidase In situ Hybridization and Detection Kit (Chemicon, S7101) ac-
cording to the manufacturer’s instructions. The number of positive cells was
counted on a total of eight sections of the control group and eight sections
of theMTP-NeuNT-treated group. Data were expressed as the number of pos-
itive (apoptotic) cells per area (mm2).
Image Acquisition
Cell fluorescence imageswere acquiredwith the fluorescence Zeiss Imager Z2
equipped with HXP 120 W lamp and ApoTome system. Lung metastasis
images were acquired using a macroscope Zeiss AXIOZoom.V16. Images
were analyzed using AxioVision 4.7.2 (Zeiss), Zen (Zeiss), and Image J (Wayne
Rasband, NIH) software.
Phosphorylation of ErbB2 Receptor on NT193 Cells
Phospho-Neu (Y1221/Y1222) cell-based colorimetric ELISA Kit (Immunoway
Biotechnology Company) was used to monitor levels of phosphorylated
mErbB2 and related total mErbB2 receptor. NT193 cells were seeded into
the wells of the 96-well plate at densities of 30,000 cells in 200 ml cell-culture
media and serum starved overnight. The cells were then treated with either
vehicle (LDS 720 mM) or MTP-NeuNT peptide for 1 hr at 106 M.mErbB2 phos-
phorylation was assessed according to the manufacturer’s instructions.
Western Blot
Before protein extraction, the cells were treated either with 106 M of MTP-
NeuNT or Vehicle (LDS, 720 mM). Protein sample preparation was completed
with Laemmli buffer supplemented with protease inhibitor (Roche tablets,
#11836145001) and 5 mM of Na orthovanadate. Proteins were resolved in
an 8% SDS/PAGE gel and transferred onto a nitrocellulose membrane (What-
man). The blots were soaked in blocking solution (TBS/1% Tween 20/5%milk)1720 Cell Reports 8, 1714–1721, September 25, 2014 ª2014 The Aufor 1 hr at RT. First antibodies (rabbit anti-phospho-akt, Rabbit anti-akt, Cell
Signaling #4060 and #9272, respectively) and mouse antiactin (Chemicon
#MAB1501R) were incubated overnight at 4C. Secondary antibodies (anti-
rabbit-HRP, GE Healthcare, #NA934V and anti-mouse-HRP, GE Healthcare,
#NXA931) were incubated 1 hr a RT in TBS/1% Tween 20/5% milk. The
revelation step was performed using streptavidin-biotinylated horseradish
peroxidase complex (Amersham #RPN1051) according to the manufacturer
instructions. Images of the immune blots were acquired and analyzed thanks
to the GENE GNOME apparatus (Syngene Bio Imaging).
Loss- and Gain-of-Function Experiments
Lentiviruses producing HEK293T cells were transfected using the JetPEI
transfection reagent (PolyPlus Transfection) with a set of two different
pGFP-C-shLenti 29MER plasmid vectors: TL320342A, TL320342B (OriGene)
and three lentivirus packaging plasmid vectors containing pMDL g/p RRE,
pRSV-rev, pMD2-VSVG (Addgene). After 48 hr, the HEK293T cells culture
media was harvested and transferred on MCF7 cells growth media containing
8 mg/ml protamine sulfate (Sigma-Aldrich) for 72 hr prior to selection with
5 mg/ml puromycin. Screening of protein knockdown was done by western
blot as described above.
Gain-of-Function Experiment
MDA-MB-231 (negative for HER2 and not sensitive to MTP-NeuNT) were
transfected with a plasmid vector PSV2neo carrying the sequence coding
for the human version of HER2 receptor. The transfection of MDA-MB231
was done with the JetPEI (Polyplus Transfection) reagent according to the
manufacturer procedure. Cells were then selected with geneticin sulfate
G418 (Life Technologies) for 10 days before using them for functional assays.
Animal Handling and In Vivo Ethical Statement
Experiments were performed according to the Guide for Care and Use of
Laboratory Animals (E67-6-482-21) and the European Directive with approval
of the regional ethical committee (reference AL/55/62/02/13). Mice received
food and water ad libitum. Animals were sacrificed using CO2. All necessary
precautions were taken to minimize pain or discomfort of the animals. Gen-
eral health status was monitored three times a week by independent ob-
servers. Sacrifice of the animal was effectuated when reaching limit ethical
endpoints.
Production of the Transgenic MMTV-NeuNT Mice
Transgenic FVB mice expressing the mutant activated form of murine ErbB2
(NeuNT) under control of the mouse mammary tumor virus (MMTV) promoter
(Muller et al., 1988) were kindly obtained from Dr. Gerhard Christofori (Univer-
sity of Basel). We generated a cohort of 20 mice receiving either 15 mg/kg of
MTP-NeuNT or vehicle (LDS, 720 mM) three times a week. Treatments were
administrated when the first palpated tumor reached 200 mm3 volume as
determined using electronic caliper.
In Vivo Imaging and Surface Rendering of mCT
In vivo mCT, equipped with dedicated anesthesia chamber, was performed on
a weekly basis at the IPHC (Institut Pluridisciplinaire Hubert Curien), Stras-
bourg, France. Acquisition parameters were 40 kVp, 250 lA, and 235 ms expo-
sures per projection in binning 2 3 2 with a projection pixel size of 100 3
100 cm2. A full image data set covered 360 in 0.47 steps for a total of 768
projections. Images were reconstructed with a cone-beam reconstruction
algorithm producing in real time a 3D image with an isotropic voxel size of
0.1 mm. The delivered dose during each microCT exam was 48 mGy. Once
the metastasis was detected in the lung, its volume was calculated as follows:
V = (4/3) *p * rx * ry * rz, where r is the radius of themetastasis and x, y, z are the
axial directions.
Statistics
Statistical analyses were performed using Mann-Whitney test (for sample n <
30), chi-square analysis (for qualitative data), extra sum of square F test (for the
mCT number of metastasis curves) using GraphPad software. p values are
given in the figure legends, and values of p < 0.05 were considered to be
statistically significant. A minimum of three independent experiments wasthors
performed for in vitro assays (proliferation, ErbB2 phosphorylation, and west-
ern blot). For in vivo experiments, the sample size calculation anticipated a
therapeutic effect of 20% for a SD of 14% and confidence interval of confi-
dence 95% (Lamorte’s Power calculation, University of Boston).
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